NCT01511692View on ClinicalTrials.gov

Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

September 30, 2007

Study Completion Date

September 30, 2007

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

liraglutide

1.8 mg/day injected subcutaneously for 4 weeks

DRUG

placebo

Liraglutide placebo, injected subcutaneously for 4 weeks

DRUG

placebo

Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks

DRUG

glimepiride

Dose individually adjusted, administered orally for 4 weeks

Trial Locations (2)

5005

Novo Nordisk Investigational Site, Adelaide

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01511692 - Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes | Biotech Hunter | Biotech Hunter